Clinical trial
Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as…
NCT00269152 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00269152 |
|---|---|
| Title | Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer |
| Official title | A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients With Completely Resected Stage Ib or II Non-Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed, cisplatin, carboplatin |
| Enrollment | 122 |
| Start date | Dec 1, 2005 |
| Primary completion | Nov 1, 2007 |
| Completion | Jul 1, 2013 |
| First posted | Dec 23, 2005 |
| Last update posted | Aug 18, 2015 |
| Countries | France, Germany, Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: